Reversing left ventricular remodeling in chronic heart failure: Surgical approaches

Kartikya Ahuja, Gregory A. Crooke, Eugene A. Grossi, Aubrey C. Galloway, Ulrich P. Jorde

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic heart failure (CHF) has become an epidemic in the United States, with approximately 550,000 new cases annually. With the evolution of pharmacotherapy targeting neurohormonal pathways, the annual mortality in subjects with New York Heart Association (NYHA) class IV CHF has dramatically improved from 52% in the seminal CONSENSUS trial to less than 20% in more recent trials. Suppression of the renin-angiotensin-aldosterone system remains the first line of neurohormonal blockade followed by the addition of selective β-adrenoreceptor blockers. For patients with NYHA class I and II symptoms, mortality rates have decreased to approximately 5% or less per year with the use of angiotensin-converting enzyme inhibitors, β-blockers and aldosterone receptor blockers. However, after achieving optimal doses of the indicated pharmacotherapy, and despite the additional benefits obtained with biventricular pacemakers, there are still many patients who continue to experience signs and symptoms of CHF. Recognizing the beneficial effects of the above treatments on left ventricular (LV) remodeling, strategies have been developed to surgically reshape the left ventricle in patients with LV dilation who have associated poor LV function. This review will discuss the techniques and recent developments regarding surgical reshaping of the dilated, dysfunctional, and remodeled left ventricle.

Original languageEnglish (US)
Pages (from-to)184-190
Number of pages7
JournalCardiology in Review
Volume15
Issue number4
DOIs
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

Ventricular Remodeling
Heart Failure
Heart Ventricles
Drug Therapy
Mineralocorticoid Receptors
Mortality
Renin-Angiotensin System
Left Ventricular Function
Angiotensin-Converting Enzyme Inhibitors
Signs and Symptoms
Dilatation
Therapeutics

Keywords

  • Batista procedure
  • Dor procedure
  • Heart failure
  • Remodeling surgery
  • Surgical ventricular reconstruction
  • Volume reduction surgery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Reversing left ventricular remodeling in chronic heart failure : Surgical approaches. / Ahuja, Kartikya; Crooke, Gregory A.; Grossi, Eugene A.; Galloway, Aubrey C.; Jorde, Ulrich P.

In: Cardiology in Review, Vol. 15, No. 4, 07.2007, p. 184-190.

Research output: Contribution to journalArticle

Ahuja, Kartikya ; Crooke, Gregory A. ; Grossi, Eugene A. ; Galloway, Aubrey C. ; Jorde, Ulrich P. / Reversing left ventricular remodeling in chronic heart failure : Surgical approaches. In: Cardiology in Review. 2007 ; Vol. 15, No. 4. pp. 184-190.
@article{b26545c67381458d97dbc56d337a059a,
title = "Reversing left ventricular remodeling in chronic heart failure: Surgical approaches",
abstract = "Chronic heart failure (CHF) has become an epidemic in the United States, with approximately 550,000 new cases annually. With the evolution of pharmacotherapy targeting neurohormonal pathways, the annual mortality in subjects with New York Heart Association (NYHA) class IV CHF has dramatically improved from 52{\%} in the seminal CONSENSUS trial to less than 20{\%} in more recent trials. Suppression of the renin-angiotensin-aldosterone system remains the first line of neurohormonal blockade followed by the addition of selective β-adrenoreceptor blockers. For patients with NYHA class I and II symptoms, mortality rates have decreased to approximately 5{\%} or less per year with the use of angiotensin-converting enzyme inhibitors, β-blockers and aldosterone receptor blockers. However, after achieving optimal doses of the indicated pharmacotherapy, and despite the additional benefits obtained with biventricular pacemakers, there are still many patients who continue to experience signs and symptoms of CHF. Recognizing the beneficial effects of the above treatments on left ventricular (LV) remodeling, strategies have been developed to surgically reshape the left ventricle in patients with LV dilation who have associated poor LV function. This review will discuss the techniques and recent developments regarding surgical reshaping of the dilated, dysfunctional, and remodeled left ventricle.",
keywords = "Batista procedure, Dor procedure, Heart failure, Remodeling surgery, Surgical ventricular reconstruction, Volume reduction surgery",
author = "Kartikya Ahuja and Crooke, {Gregory A.} and Grossi, {Eugene A.} and Galloway, {Aubrey C.} and Jorde, {Ulrich P.}",
year = "2007",
month = "7",
doi = "10.1097/CRD.0b013e318053d13f",
language = "English (US)",
volume = "15",
pages = "184--190",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Reversing left ventricular remodeling in chronic heart failure

T2 - Surgical approaches

AU - Ahuja, Kartikya

AU - Crooke, Gregory A.

AU - Grossi, Eugene A.

AU - Galloway, Aubrey C.

AU - Jorde, Ulrich P.

PY - 2007/7

Y1 - 2007/7

N2 - Chronic heart failure (CHF) has become an epidemic in the United States, with approximately 550,000 new cases annually. With the evolution of pharmacotherapy targeting neurohormonal pathways, the annual mortality in subjects with New York Heart Association (NYHA) class IV CHF has dramatically improved from 52% in the seminal CONSENSUS trial to less than 20% in more recent trials. Suppression of the renin-angiotensin-aldosterone system remains the first line of neurohormonal blockade followed by the addition of selective β-adrenoreceptor blockers. For patients with NYHA class I and II symptoms, mortality rates have decreased to approximately 5% or less per year with the use of angiotensin-converting enzyme inhibitors, β-blockers and aldosterone receptor blockers. However, after achieving optimal doses of the indicated pharmacotherapy, and despite the additional benefits obtained with biventricular pacemakers, there are still many patients who continue to experience signs and symptoms of CHF. Recognizing the beneficial effects of the above treatments on left ventricular (LV) remodeling, strategies have been developed to surgically reshape the left ventricle in patients with LV dilation who have associated poor LV function. This review will discuss the techniques and recent developments regarding surgical reshaping of the dilated, dysfunctional, and remodeled left ventricle.

AB - Chronic heart failure (CHF) has become an epidemic in the United States, with approximately 550,000 new cases annually. With the evolution of pharmacotherapy targeting neurohormonal pathways, the annual mortality in subjects with New York Heart Association (NYHA) class IV CHF has dramatically improved from 52% in the seminal CONSENSUS trial to less than 20% in more recent trials. Suppression of the renin-angiotensin-aldosterone system remains the first line of neurohormonal blockade followed by the addition of selective β-adrenoreceptor blockers. For patients with NYHA class I and II symptoms, mortality rates have decreased to approximately 5% or less per year with the use of angiotensin-converting enzyme inhibitors, β-blockers and aldosterone receptor blockers. However, after achieving optimal doses of the indicated pharmacotherapy, and despite the additional benefits obtained with biventricular pacemakers, there are still many patients who continue to experience signs and symptoms of CHF. Recognizing the beneficial effects of the above treatments on left ventricular (LV) remodeling, strategies have been developed to surgically reshape the left ventricle in patients with LV dilation who have associated poor LV function. This review will discuss the techniques and recent developments regarding surgical reshaping of the dilated, dysfunctional, and remodeled left ventricle.

KW - Batista procedure

KW - Dor procedure

KW - Heart failure

KW - Remodeling surgery

KW - Surgical ventricular reconstruction

KW - Volume reduction surgery

UR - http://www.scopus.com/inward/record.url?scp=34250768222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250768222&partnerID=8YFLogxK

U2 - 10.1097/CRD.0b013e318053d13f

DO - 10.1097/CRD.0b013e318053d13f

M3 - Article

C2 - 17575482

AN - SCOPUS:34250768222

VL - 15

SP - 184

EP - 190

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 4

ER -